Welcome to your daily round-up of everything happening in the world of neurorehab.
Research
Scientists uncover new molecular drivers of Alzheimer’s
In a new study, researchers used a new technique for studying single, living brain cells affected by Alzheimer’s disease. By measuring the electrical activity of single neurons and the protein levels within those neurons, the scientists discovered new molecules linked to Alzheimer’s. The hope is these molecules could be targeted by drugs to treat or slow the progression of the neurodegenerative disease in the future.
Naturally occurring substance in fruits can improve treatment of Alzheimer’s
A substance naturally occurring in i.a. pomegranates, strawberries and walnuts can improve memory and treatment of Alzheimer’s disease, a new study conducted at the University of Copenhagen concludes.
Researchers previously discovered that a specific molecule, nicotinamide riboside (NAD supplement), plays a key role in neurodegenerative diseases such as Alzheimer’s and Parkinson’s, as it actively helps remove damaged mitochondria from the brain. The results of the new study show that a substance found in pomegranates, urolithin A, removes weak mitochondria from the brain just as effectively as NAD supplement.
Stroke-care metrics improve with stroke centre certification and coordinators
External evaluation of the Medical University of South Carolina’s telestroke program confirms that stroke centre certification and stroke coordinators improve stroke-care metrics. NORC, which stands for National Opinion Research Center, and MUSC researchers report their findings in the Journal of Stroke & Cerebrovascular Diseases.
Company updates
Onward publishes year-to-date highlights
Onward Medical has published its highlights from Q1 2024, including successfully raising EUR 20m in equity capital. The company also submitted its FDA De Novo application for its ARC-EX® System and results from the Up-LIFT trial were published in Nature Medicine.
Sinaptica Therapeutics selected for StartUp Health’s Alzheimer’s Moonshot
Sinaptica Therapeutics, a clinical-stage company leading the development of a new class of personalised neuromodulation therapeutics to treat Alzheimer’s and other neurodegenerative diseases, has been selected to join StartUp Health’s Alzheimer’s Moonshot. This new initiative and global community of founders and funders collaborating to prevent, diagnose, manage, and ultimately cure Alzheimer’s disease is supported by the Alzheimer’s Drug Discovery Foundation (ADDF) and Gates Ventures.
